The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Tel Aviv Sourasky Medical Center

Status: Unknown

Conditions: Primary Liver Cancer

Treatments: Dietary Supplement: Branched-chain amoni acids (BCAA); Dietary Supplement: non-BCAA protein supplement

Study type: Interventional

Funder types: Other

Identifiers

NCT02327819

0440-14-TLV

Details and patient eligibility

About

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown.

The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed primary liver cancer
• viral or Nonalcoholic Steatohepatitis Cirrhosis
• Cirrhosis rated Child-Pugh A
• liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A

Exclusion criteria

• Age (over 65)
• liver condition rated Child-Pugh B/C
• GI/Absorption issues
• patients given a treatment before surgery

Trial design

60 participants in 2 patient groups

BCAA supplement

Active Comparator group

Description:

Branched-chain amino acids supplement, 12 g/day

Treatment:

Dietary Supplement: Branched-chain amoni acids (BCAA)

non-BCAA protein supplement

Sham Comparator group

Description:

non-BCAA protein supplement

Treatment:

Dietary Supplement: non-BCAA protein supplement